fluoropyrimidine S-1; tegafur/5-chloro-2,4-dihydroxypyridine/potassium oxonate
Jump to navigation
Jump to search
Indications
- used in combination with chemoradiation for treatment of esophageal cancer
Adverse effects
- esophagitis (17%), pneumonitis, & thrombocytopenia, leukopenia (13%)
Mechanism of action
- designed to have enhanced cancer activity & less toxicity than fluorouracil + cisplatin
More general terms
References
- ↑ Ji Y, Du X, Zhu W et al Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer. A Multicenter Randomized Phase 3 Clinical Trial. JAMA Oncol. Published online August 5, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34351356 https://jamanetwork.com/journals/jamaoncology/fullarticle/2782741
Eads JR, Haller DG Primary Chemoradiotherapy for Older Patients With Esophageal Cancer. JAMA Oncol. Published online August 5, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34351378 https://jamanetwork.com/journals/jamaoncology/fullarticle/2782745